medicine

Q1-Q2 2026 is lining up to be big for next gen GLP-1s with triple agonists expected to get approval.

It will be led by the triple Gs

Lily has retarutide in the pipeline with phase 3 finishing soon

Novo just signed a deal with Chinese pharma company United Biotech for global launch. 

Most looking forward to the lean muscle mass preservation data on these 3Gs which many insiders are telling me may actually increase muscle mass!

A big reason for this acceleration is that Ozempic will be out of patent in China in Q1 2026 so incentivizing a lot of combos as well such as CagriSema

Q1-Q2 2026 is lining up to be big for next gen GLP-1s with triple agonists expected to get approval.

It will be led by the triple Gs

Lily has retarutide in the pipeline with phase 3 finishing soon

Novo just signed a deal with Chinese pharma company United Biotech for global launch. 

Most looking forward to the lean muscle mass preservation data on these 3Gs which many insiders are telling me may actually increase muscle mass!

A big reason for this acceleration is that Ozempic will be out of patent in China in Q1 2026 so incentivizing a lot of combos as well such as CagriSema

https://newatlas.com/disease/obesity/obesity-novo-nordisk-lilly/

Physician always trying to learn, passionate about healthspan and precision medicine.

omarsaleem.xyz

top five countries using Ozempic for weight loss (including off-label use and search interest) are:
	1.	United States
	2.	Denmark
	3.	United Kingdom
	4.	Australia
	5.	Germany 
top five countries with the highest obesity rates (percentage of adults with BMI ≥ 30) are:
	1.	Samoa – 81.48%
	2.	Nauru – 74.97%
	3.	Tonga – 74.48%
	4.	Tuvalu – 69.25%
	5.	Saint Kitts and Nevis – 54.54%

Drugs are for rich class only .?

Hope one day pharmaceutical company will contribute more for global
Health Care not just making money asap